ADPT FY2025 SEC EDGAR DEF 14A #76 of 168 in industry

Adaptive Biotechnologies Corp CEO pay ratio

The CEO earned $9.1M in FY2025 against median worker pay of $194,620 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
WA
Filing date
2026-04-24
Industry
Chemicals & Pharmaceuticals
Industry rank
#76/168

Data updated August 2026

Subscribe to Adaptive Biotechnologies Corp CEO pay filing updates (RSS)

CEO-to-worker pay ratio
47:1
Below Average (Scale: 0–1000:1)
CEO pay
$9.1M
Median worker
$194,620

Answer first

Adaptive Biotechnologies Corp's FY2025 CEO total of $9.1M ranks #584 of 1,423 complete filings; its 47:1 pay ratio ranks #994. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $194,620. Industry placement uses the FY2025 SIC-28 peer cohort (# 76 of 168, 55th percentile - above the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#584
$9.1M of 1,423 FY2025
Ratio rank
#994
47:1 of 1,423
Industry pct
55th
above the industry median pay ratio

How Adaptive Biotechnologies Corp ranks nationally

Adaptive Biotechnologies Corp CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$9,147,140 Top 41% higher than 59% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). This entry sits in this band. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Adaptive Biotechnologies Corp vs. Chemicals & Pharmaceuticals peers

CEO total pay ($9.1M) against pay ratio (47:1) for Adaptive Biotechnologies Corp (marked) and its 4 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both7346514.710388126.41342973816471349.719512961.341.7:143.4:145:146.6:148.3:1CEO total payPay ratio (CEO : median worker)Adaptive Biotechnologies Corp, CEO total pay: 9147140 · Pay ratio (CEO : median worker): 47:1Adaptive Biotechnologies CorpMadrigal Pharmaceuticals, Inc., CEO total pay: 18959941 · Pay ratio (CEO : median worker): 47:1Madrigal Pharmaceuticals, Inc.Corcept Therapeutics Inc, CEO total pay: 15303551 · Pay ratio (CEO : median worker): 46:1Corcept Therapeutics IncAlnylam Pharmaceuticals, Inc., CEO total pay: 14984640 · Pay ratio (CEO : median worker): 48:1Alnylam Pharmaceuticals, Inc.Vaxcyte, Inc., CEO total pay: 14585904 · Pay ratio (CEO : median worker): 48:1Vaxcyte, Inc.
Adaptive Biotechnologies Corp vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Adaptive Biotechnologies Corp's structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Adaptive Biotechnologies Corp

Complete DEF 14A pay-ratio filings for this CIK across FY2024–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
47:1
FY2025
vs prior FY
+18:1
from FY2024 29:1
CEO $ YoY
+85%
$9.1M latest
Filings shown
2
FY2024–2025
Adaptive Biotechnologies Corp CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2024 $4.9M - $170,306 29:1 -
2025 $9.1M +85% $194,620 47:1 +18:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1478320, FY2024–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
47:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$9.1M
Companies in Industry
168
vs. Industry Median
Above
#76 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Adaptive Biotechnologies Corp: MODEST · HEAVY pay ratio

Adaptive Biotechnologies Corp's 47:1 ratio ranks #994 of 1,423 FY2025 complete filings (lower third by ratio). the CEO earned 47× the median employee ($194,620) in FY2025.

Median employee $194,620 (ELITE-MED); MODEST · HEAVY stamps put about 47 median-wage years per CEO year.

CEO Total Pay

$9.1M

FY2025 Summary Compensation, above median

Pay Ratio

47:1

Below typical

Adaptive Biotechnologies Corp in the lower-ratio third

Adaptive Biotechnologies Corp's 47:1 ratio ranks #994 of 1,423 FY2025 complete filings (lower third by ratio). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Adaptive Biotechnologies Corp's $9.1M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #584 and ratio rank #994 split - treat 47:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$9.1M
Median Employee Pay
$194,620
Pay Ratio
47:1
Filing Date
2026-04-24

Company Info

Ticker
ADPT
CIK
1478320
Industry
Chemicals & Pharmaceuticals
SIC Code
2836
State
WA
View SEC filings →
SEC EDGAR DEF 14A for CIK 1478320, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Adaptive Biotechnologies Corp's 47:1 ratio ranks #994 of 1,423 FY2025 complete filings (lower third by ratio).

Read with Adaptive Biotechnologies Corp

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · HEAVY · ELITE-MED.

Idex Corp /de/ · HEAVY

ABS(ceo_total_comp) peer at $9.1M (Δ $3K lighter vs Adaptive Biotechnologies Corp); MID · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Allegion plc · HEAVY

ABS(ceo_total_comp) peer at $9.2M (Δ $8K heavier vs Adaptive Biotechnologies Corp); MID · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Aes Corp · HEAVY

ABS(ceo_total_comp) peer at $9.1M (Δ $17K lighter vs Adaptive Biotechnologies Corp); MID · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Everest Group, Ltd. · HEAVY

ABS(ceo_total_comp) peer at $9.2M (Δ $19K heavier vs Adaptive Biotechnologies Corp); MODEST · ELITE-MED vs this page's MODEST · HEAVY · ELITE-MED.
Madrigal Pharmaceuticals, Inc. (SIC 28 pole)

Madrigal Pharmaceuticals, Inc. stamps MODEST · PEAK nearest in-SIC by ABS(pay_ratio) to Adaptive Biotechnologies Corp's MODEST filing.
National dual ranks · #584/#994

Adaptive Biotechnologies Corp's FY2025 package sits #584 by CEO dollars and #994 by ratio under HEAVY · MODEST.
Ratio primer · MODEST

Adaptive Biotechnologies Corp's MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Adaptive Biotechnologies Corp (CIK 1478320), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.